Pregnancy specific biological substances

Specific Biologics Announces Additional Investment and Appointment of Experienced Biotechnology Leader Steven Kanner, PhD, to the Board of Directors

Retrieved on: 
Tuesday, October 10, 2023
ADMAR, Cystic Fibrosis Foundation, MBA, Doctor of Philosophy, Research, Pregnancy specific biological substances, G.H. Raisoni Department of Microbiology and Biotechnology, Bristol Myers Squibb, Berkeley, MD, Master of Science, Organization, Therapy, Liver, Genetics, University, Mutation, Rachel Haurwitz, Disease, University of Miami Division of Surgical Neurooncology, Arrowhead Pharmaceuticals, Leonard M. Miller School of Medicine, Cystic fibrosis, Annual Review of Cancer Biology, University of Virginia Cancer Center, Acute leukemia, DSM-IV codes, Gene editing, Astex Pharmaceuticals, Specific, Dasatinib, CNS, Patient, Vaccine, Pharmaceutical industry, Investment, Microbiology, Immunology

Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase® platform gene editors to build a pipeline of treatments for serious genetic diseases.

Key Points: 
  • Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase® platform gene editors to build a pipeline of treatments for serious genetic diseases.
  • TORONTO, Oct. 10, 2023 /PRNewswire/ - Specific Biologics Inc. ("Specific"), a venture-backed, early-stage genome editing company, is pleased to announce it has appointed Steven Kanner, PhD, as an Independent Director.
  • The appointment coincides with renewed investment from Lumira Ventures and adMare BioInnovations to advance the preclinical development of therapeutics based on Specific's proprietary Dualase® platform gene editors.
  • The additional investment from Lumira Ventures and adMare BioInnovations will be used to advance preclinical testing of Dualase gene editors in liver, ocular and CNS disorders.

Specific Biologics Closes Seed Financing with Industry Leaders Lumira Ventures and adMare BioInnovations

Retrieved on: 
Thursday, December 16, 2021
Organization, Western University, Schulich School of Medicine & Dentistry, Ecosystem, Genomics, Cell, Intelligence, Genome, Gene editing, Growth, Industry, Biotron (Western University), Medicine, Lists of diseases, Bachelor of Engineering, CEO, Research, Gene, Robotics, Patient, Therapy, St John's Innovation Centre, DNA, Efficiency, Multimedia, ADMAR, Partnership, Vaccine, Pharmaceutical industry, Medical device, Pregnancy specific biological substances, Investment, Specific

TORONTO, Dec. 16, 2021 /PRNewswire/ - Specific Biologics Inc. ("Specific") today announced that it has closed its first institutional financing, led by Lumira Ventures and adMare BioInnovations which have recently established an innovative partnership to build Canadian life sciences companies.

Key Points: 
  • TORONTO, Dec. 16, 2021 /PRNewswire/ - Specific Biologics Inc. ("Specific") today announced that it has closed its first institutional financing, led by Lumira Ventures and adMare BioInnovations which have recently established an innovative partnership to build Canadian life sciences companies.
  • "We are excited to work alongside adMare and the Specific team to grow the company and bring transformative therapies to patients."
  • "The investment in Specific Biologics stems from a new partnership between adMare and Lumira Ventures," commented Dr. Frdric Lematre Auger, Managing Partner, Investments with adMare.
  • Specific Biologics Inc. ("Specific") is a venture-backed early-stage biotechnology company on a mission to develop novel gene editing technologies to treat diseases through precision gene editing.

Specific Biologics Inc. Announces Therapeutic Development Award from the Cystic Fibrosis Foundation

Retrieved on: 
Tuesday, December 7, 2021
Technology, Therapy, CF, Cystic fibrosis, Disease, Cystic Fibrosis Foundation, CFTR, Pregnancy specific biological substances, Gene, DNA, Patient, Lung, CEO, Gene editing, Specific, Multimedia, Genome, Cell, Vaccine, Antibiotics

Award to help fund preclinical studies to apply Specific Biologics' Dualase gene editing platform as a potential treatment for cystic fibrosis patients with nonsense genetic mutations.

Key Points: 
  • Award to help fund preclinical studies to apply Specific Biologics' Dualase gene editing platform as a potential treatment for cystic fibrosis patients with nonsense genetic mutations.
  • TORONTO, Dec. 7, 2021 /PRNewswire/ -Specific Biologics Inc. ("Specific"), an early-stage biotechnology company developing novel gene editing technologies, today announced that it will receive more than US$527,000 to support the preclinical development of its Dualase gene editing platform to target a set of cystic fibrosis (CF)-causing nonsense mutations where patients currently have fewer therapeutic options available.
  • We are truly grateful for the support of this Cystic Fibrosis Foundation award which will allow us to apply our Dualase gene editing technology to several frequent CFTR nonsense mutations."
  • Specific Biologics Inc. ("Specific") is a venture-backed early-stage biotechnology company on a mission to develop novel gene editing technologies to treat diseases through precision gene editing.

Americord Registry Introduces Placental Tissue 2.0™, Amniotic Membrane Biobanking for Families

Retrieved on: 
Monday, July 15, 2019
Branches of biology, Stem cells, Biology, Life sciences, Amniotic epithelial cell, Mesenchymal stem cell, Amniocentesis, Amniotic stem cell bank, Cord blood bank, Wound healing, Cord lining, Pregnancy specific biological substances

NEW YORK, July15,2019 /PRNewswire/ --Americord Registry announced today the launch of its newest stem cell banking product, Placental Tissue 2.0.

Key Points: 
  • NEW YORK, July15,2019 /PRNewswire/ --Americord Registry announced today the launch of its newest stem cell banking product, Placental Tissue 2.0.
  • Americord was one of the first family cord blood banks to store placental tissue and now offers this exciting product, which stores live amniotic membrane (AM), a first for the industry.
  • Placental Tissue 2.0 allows a family to store two types of valuable stem cells: mesenchymal stem cells (MSCs), and a variety of stem cell called amniotic epithelial cells (or AECs).
  • Placental Tissue 2.0 offers almost double the stem cell output, allowing immediate potential for surgical wound healing as well as many other uses," said Martin Smithmyer, CEO of Americord.